Repatha vs Losartan: Cost and Access Head-to-Head

Why These Two Drugs Get Compared

Patients searching "Repatha vs Losartan" are typically managing overlapping cardiometabolic risks: high cholesterol, high blood pressure, or both. The comparison arises because both medications reduce cardiovascular events, but they do so through entirely different mechanisms and at vastly different price points.

Repatha (evolocumab) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). By blocking PCSK9, it prevents LDL receptor degradation on hepatocytes, allowing the liver to clear more LDL particles from the bloodstream. Losartan blocks the angiotensin II type 1 receptor, reducing vasoconstriction and aldosterone secretion to lower blood pressure. The two drugs occupy separate pharmacologic categories and address separate risk factors. A patient with both uncontrolled LDL and hypertension may need both, not one or the other.

The 2018 ACC/AHA cholesterol guidelines position PCSK9 inhibitors as add-on therapy for patients with atherosclerotic cardiovascular disease (ASCVD) whose LDL remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe (ACC/AHA 2018 guideline). Losartan, by contrast, is a first-line antihypertensive recommended in the 2017 ACC/AHA hypertension guideline for adults with blood pressure at or above 130/80 mmHg (2017 ACC/AHA hypertension guideline).

Efficacy: What the Landmark Trials Show

The FOURIER trial (N=27,564) randomized patients with stable ASCVD already on statin therapy to evolocumab 140 mg every 2 weeks (or 420 mg monthly) versus placebo. At a median follow-up of 2.2 years, evolocumab reduced the primary composite endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15% (HR 0.85, 95% CI 0.79 to 0.92, P<0.001) (Sabatine et al., NEJM 2017). Median LDL dropped from 92 mg/dL to 30 mg/dL.

The LIFE trial (N=9,193) compared losartan-based therapy to atenolol-based therapy in patients with hypertension and left ventricular hypertrophy on ECG. Over a mean follow-up of 4.8 years, losartan reduced the primary composite of cardiovascular death, stroke, or myocardial infarction by 13% (adjusted HR 0.87, 95% CI 0.77 to 0.98, P=0.021), driven largely by a 25% stroke risk reduction (Dahlöf et al., Lancet 2002).

No head-to-head trial has compared evolocumab directly against losartan. That trial would not be clinically logical because the drugs target different pathophysiologies. Interpreting the 15% MACE reduction from FOURIER alongside the 13% composite reduction from LIFE requires caution: the populations, comparators, endpoints, and follow-up durations differ significantly.

Cost Comparison: List Price, Net Price, and Out-of-Pocket

This is where the gap between these two drugs becomes most pronounced. Drug pricing matters because even a highly effective therapy delivers zero benefit if a patient cannot afford to fill it.

Repatha carries a wholesale acquisition cost (WAC) of approximately $5,850 per year as of 2025, following Amgen's 2018 list price reduction from $14,100. The Institute for Clinical and Economic Review (ICER) had previously estimated a cost-effective threshold of roughly $4,500 to $8,000 per year for PCSK9 inhibitors at their revised prices (ICER PCSK9 evidence report). Net-of-rebate cost to payers is lower, estimated between $3,500 and $5,000 annually, though these figures vary by contract.

Generic losartan costs between $4 and $30 per month depending on dose (25 mg, 50 mg, or 100 mg) and pharmacy. GoodRx cash pricing as of early 2026 shows 30 tablets of losartan 50 mg for approximately $8 to $15 without insurance. That translates to $96 to $180 per year out of pocket, a fraction of Repatha's cost even after copay assistance.

The annual cost ratio is roughly 30:1 to 60:1 in favor of losartan, though this comparison only makes clinical sense when a patient's primary risk factor is the one the cheaper drug addresses.

Insurance Coverage and Prior Authorization

Losartan faces almost no formulary barriers. It sits on Tier 1 (preferred generic) of virtually every commercial, Medicare Part D, and Medicaid formulary in the United States. No prior authorization, step therapy, or quantity limits apply in standard plans.

Repatha coverage is more complex. Most commercial insurers and Medicare Part D plans cover evolocumab but require prior authorization documenting that the patient has ASCVD or familial hypercholesterolemia (FH), has tried and failed maximally tolerated statin therapy, and often has also tried ezetimibe. Step therapy requirements vary by plan. The Centers for Medicare and Medicaid Services (CMS) issued guidance in 2023 encouraging Part D plans to reduce barriers for PCSK9 inhibitors in high-risk populations, and several large plans (UnitedHealthcare, Aetna, Cigna) have since relaxed some step-therapy criteria for patients with documented ASCVD and LDL above 70 mg/dL on maximum therapy (FDA evolocumab label).

Denial rates for PCSK9 inhibitors have improved but remain significant. A 2019 analysis in the Journal of the American College of Cardiology found that approximately 53% of initial PCSK9 inhibitor prescriptions were rejected by insurers, though appeal success rates exceeded 80% when proper documentation was submitted (Navar et al., JACC 2019).

"For patients who clearly meet guideline criteria for PCSK9 inhibition, the prior-authorization process should not be a clinical barrier. Clinicians need to submit documentation proactively," the 2022 National Lipid Association position statement noted (NLA position, J Clin Lipidol).

Patient Assistance Programs

Amgen's Repatha copay card reduces out-of-pocket cost to as low as $5 per month for commercially insured patients with a valid prescription and prior authorization approval. Patients without commercial insurance (including those on Medicare or Medicaid) can apply to the Amgen Safety Net Foundation for free drug supply. Eligibility is income-based, generally set at or below 400% of the federal poverty level.

Losartan rarely requires copay assistance because its generic price is already low. Manufacturer copay programs do not exist for generic losartan. Patients paying cash can use discount programs (GoodRx, RxSaver, Mark Cuban Cost Plus Drugs) to find prices below $10 per month.

For a commercially insured patient who qualifies for the Amgen copay card, the effective monthly cost of Repatha ($5) approaches the cash price of generic losartan. The catch: that $5 copay relies on maintaining commercial coverage with an approved prior authorization. Any lapse in insurance, job change, or formulary shift resets the access equation.

Safety and Tolerability Profiles

Evolocumab's most common adverse events in FOURIER were injection-site reactions (1.6% vs. 1.5% placebo), upper respiratory infections, and nasopharyngitis. Serious adverse events did not differ significantly between groups. A 2020 open-label extension of FOURIER (FOURIER-OLE) followed patients for a median of 5 years and found no increase in neurocognitive events, new-onset diabetes, or hemorrhagic stroke with sustained LDL levels below 20 mg/dL (O'Donoghue et al., Circulation 2022).

Losartan's side-effect profile is well-established over three decades of use. Common effects include dizziness, hyperkalemia (particularly with renal impairment or potassium-sparing diuretics), and upper respiratory infections. Losartan carries a black-box warning against use in pregnancy (all ARBs do) due to fetal renal toxicity. Angioedema is rare but reported.

Neither drug carries a high discontinuation rate from side effects. FOURIER showed a 2.2% dropout rate for evolocumab due to adverse events, compared to 2.3% for placebo. Real-world tolerability data for losartan from the LIFE trial showed a 9.4% discontinuation rate over 4.8 years, compared to 14.5% for atenolol.

Who Gets Which Drug (and Who Might Need Both)

The clinical decision between Repatha and losartan is not either/or for most cardiometabolic patients. These drugs address fundamentally different risk factors. The prescribing algorithm follows the risk factor, not a head-to-head preference.

A patient with ASCVD and LDL persistently above 70 mg/dL despite maximally tolerated statin plus ezetimibe is a guideline-appropriate candidate for evolocumab. A patient with hypertension (systolic at or above 130 mmHg) and no compelling indication for a different antihypertensive class is a candidate for losartan. A patient with both conditions may receive both drugs concurrently. No pharmacokinetic interaction between evolocumab and losartan has been reported; PCSK9 inhibitors are cleared by the reticuloendothelial system, not hepatic CYP enzymes, so drug-drug interactions are minimal.

"The decision to add a PCSK9 inhibitor should be driven by residual ASCVD risk after optimizing statin therapy, not by a comparison to antihypertensives," according to the 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies (2022 ACC Expert Consensus).

For patients with heterozygous familial hypercholesterolemia (HeFH), evolocumab is indicated regardless of ASCVD status when LDL targets are not met. Losartan has no role in lipid management.

Access Disparities and Real-World Prescribing Patterns

Cost and coverage barriers shape who actually receives PCSK9 inhibitors. A 2021 study in JAMA Network Open found that among eligible patients with ASCVD and LDL above 70 mg/dL, only 3.5% filled a PCSK9 inhibitor prescription, despite clear guideline eligibility (Zafrir et al., JAMA Netw Open 2021). Racial and socioeconomic disparities compound the problem: Black patients and those with lower household incomes were significantly less likely to receive PCSK9 inhibitor prescriptions than White patients with equivalent LDL levels.

Losartan faces no comparable access gap. Its generic availability since 2010, Tier 1 formulary placement, and sub-$15 monthly cost mean that financial barriers to ARB therapy are minimal. The 2017 ACC/AHA hypertension guidelines note that ARBs and ACE inhibitors are among the most widely prescribed drug classes in the United States, with combined annual prescriptions exceeding 250 million (Whelton et al., JACC 2018).

The access disparity raises an important cost-effectiveness question. A 2018 analysis published in JAMA Cardiology estimated the cost per quality-adjusted life-year (QALY) for evolocumab at $141,700 at its original list price and approximately $74,000 to $93,000 at the reduced price of $5,850 per year, depending on ASCVD risk stratification (Kazi et al., JAMA Cardiol 2017). For losartan, the cost per QALY in hypertension management is estimated below $15,000, well within conventional willingness-to-pay thresholds.

Biosimilar Horizon for Evolocumab

No biosimilar for evolocumab has been approved by the FDA as of May 2026. Amgen's patents on Repatha extend through the late 2020s, though several patent challenges are underway. The arrival of biosimilar evolocumab could reduce cost by 20% to 40%, based on the pattern seen with biosimilar adalimumab (Humira) and biosimilar bevacizumab. Until biosimilars reach market, the cost differential between evolocumab and losartan will remain substantial.

Samsung Bioepis and Teva have both disclosed biosimilar PCSK9 programs. If biosimilar evolocumab enters the market at a 30% discount, the annual WAC would drop to approximately $4,100, still more than 10 times the annual cost of losartan but potentially below the $50,000/QALY threshold for high-risk ASCVD patients.

Practical Cost-Reduction Strategies for Repatha

For patients prescribed evolocumab who face cost barriers, several strategies can reduce out-of-pocket spending. Enroll in the Amgen copay card program before filling the first prescription. If prior authorization is denied, file an appeal within 30 days and include documentation of statin intolerance or inadequate LDL response on maximally tolerated therapy plus ezetimibe. Specialty pharmacies affiliated with your insurer often offer lower copays than retail pharmacies. For Medicare patients, the Inflation Reduction Act's $2,000 annual Part D out-of-pocket cap (effective 2025) may reduce Repatha costs significantly for beneficiaries who previously fell into the coverage gap (CMS Part D redesign, 2024).

For losartan, no special cost-reduction strategy is needed. Cash-pay patients should compare prices across pharmacies; Mark Cuban's Cost Plus Drugs lists losartan 50 mg #30 at $3.60 plus a $5 dispensing fee.